贝林妥欧单抗治疗难治/复发儿童急性B淋巴细胞白血病2例

Application of Blinatumomab in treatment of pediatric refractory/relapsed B-lineage acute lymphoblastic leukemia in 2 cases

对2019年9月至2021年5月北京大学人民医院儿科收治的2例应用贝林妥欧单抗治疗的难治/复发急性B淋巴细胞白血病(ALL-B)患儿的临床资料进行回顾性分析。2例患儿治疗1个疗程后均获得血液学缓解,输注过程中观察到2级细胞因子释放综合征(CRS),无严重不良反应。例1缓解后桥接造血干细胞移植,目前为无病存活状态。例2后续巩固化疗中,目前为无病存活状态。贝林妥欧单抗作为新型双特异性抗体,对难治/复发ALL-B展现出较高的缓解率和更少的不良事件,可作为高肿瘤负荷患者免疫治疗的候选。

The clinical data of two children with refractory/relapsed acute B-lymphoblastic leukemia(ALL-B)treated with Blinatumomab in Department of Pediatrics,Peking University People′s Hospital from September 2019 to May 2021 were retrospectively analyzed.After 1 course of Blinatumomab infusion,both children achieved complete hematologic remission.During the infusion process,grade 2 cytokine release syndrome(CRS)was observed,and there were no fatal adverse reactions.One case underwent bridging hematopoietic stem cell transplantation after remission and achieves disease-free survival currently.The other case is still alive after subsequent consolidation chemotherapy.As a novel bispecific antibody,Blinatumomab has a good response rate to refractory/relapsed ALL-B and induces fewer adverse events,so it can be used as a candidate immunotherapy for patients with high tumor burden.